Omar Almousalli, MD
Cardiovascular Disease · Festus, MONPI 1134161904
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,487 of the $16,118 with a category attached, or 89.9%. It is spread thinly across 50 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,029 and has fallen 63.7% since, to $1,462 in 2025.
Across 772 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novartis$2K
- Boehringer Ingelheim$1K
- Johnson & Johnson$1K
- Biotronik Inc.$939
- Abiomed$891
- plus $9K from 44 others
Across 44 payments — averaging $15,320 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$510K
- Amgen$76K
- Boehringer Ingelheim International GmbH$70K
- Boehringer Ingelheim Pharma GmbH & Co.kg$13K
- E.r. Squibb & Sons, L.L.C.$4K
- Boehringer Ingelheim$1K
- plus $941 from 1 others
What the payments were for
- Grants$550%
- Travel & lodging$1,5259%
- Food & beverage$14,48790%
- Education$520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,118 in reported general payments places this provider in the 85th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 359 | $352,030 |
| XareltoRivaroxaban | 223 | $263,550 |
| JardianceEmpagliflozin | 129 | $149,785 |
| EntrestoSacubitril/Valsartan | 71 | $67,499 |
| BrilintaTicagrelor | 78 | $43,463 |
| Repatha SureclickEvolocumab | 27 | $37,916 |
| MultaqDronedarone Hcl | 22 | $17,745 |
| Praluent PenAlirocumab | 17 | $12,827 |
| VascepaIcosapent Ethyl | 13 | $9,989 |
| Rosuvastatin Calcium | 683 | $8,375 |
| Metoprolol Succinate | 702 | $8,283 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $5,563 |
| Icosapent Ethyl | 13 | $5,174 |
| Atorvastatin Calcium | 435 | $4,028 |
| Ranolazine ErRanolazine | 42 | $3,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $485 | $352,030359 claims |
| Johnson & JohnsonXarelto | $1,069 | $263,550223 claims |
| Boehringer IngelheimJardiance | $1,145 | $149,785129 claims |
| NovartisEntresto | $1,564 | $67,49971 claims |
| AstraZenecaBrilinta | $728 | $43,46378 claims |
| Sanofi-aventis U.S. LLCMultaq | $731 | $17,74522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Festus
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James FairlambColumbia$342K
- James EllisonChesterfield$267K
- Osler Jay GuzonSaint Louis$211K
- Matthew FraleyFlorissant$183K
- Mohammad TahirSaint Louis$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.